RU98103503A - APPLICATION OF BASIC AMINO ACIDS AND THEIR DERIVATIVES TO REDUCE THE CONTENT OF CERAMIDES, PHARMACEUTICAL COMPOSITION - Google Patents

APPLICATION OF BASIC AMINO ACIDS AND THEIR DERIVATIVES TO REDUCE THE CONTENT OF CERAMIDES, PHARMACEUTICAL COMPOSITION

Info

Publication number
RU98103503A
RU98103503A RU98103503/14A RU98103503A RU98103503A RU 98103503 A RU98103503 A RU 98103503A RU 98103503/14 A RU98103503/14 A RU 98103503/14A RU 98103503 A RU98103503 A RU 98103503A RU 98103503 A RU98103503 A RU 98103503A
Authority
RU
Russia
Prior art keywords
diseases
carnitine
pharmacologically acceptable
basic amino
amino acid
Prior art date
Application number
RU98103503/14A
Other languages
Russian (ru)
Other versions
RU2179850C2 (en
Inventor
Моретти Сония
Original Assignee
Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Мендес С.Р.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT95RM000545A external-priority patent/IT1277898B1/en
Application filed by Сигма-Тау Индустрие Фармасьютике Риуните С.П.А., Мендес С.Р.Л. filed Critical Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Publication of RU98103503A publication Critical patent/RU98103503A/en
Application granted granted Critical
Publication of RU2179850C2 publication Critical patent/RU2179850C2/en

Links

Claims (5)

1. Применение основной аминокислоты или ацилированной основной аминокислоты, выбранной из группы, состоящей из аргинина, лизина, гистидина и орнитина или их фармакологически приемлемых солей, L-карнитина или ацил- L-карнитина, где ацил выбирают из группы, включающей ацетил, пропионил, бутирил, валерил, и изовалерил, или их фармакологически приемлемых солей, для получения лекарственного препарата для профилактики или лечения заболеваний или цитологических нарушений, вызванных высоким содержанием церамидов.1. The use of a basic amino acid or acylated basic amino acid selected from the group consisting of arginine, lysine, histidine and ornithine or their pharmacologically acceptable salts, L-carnitine or acyl-L-carnitine, where the acyl is selected from the group consisting of acetyl, propionyl, butyryl, valeryl, and isovaleryl, or their pharmacologically acceptable salts, for the manufacture of a medicament for the prevention or treatment of diseases or cytological disorders caused by a high content of ceramides. 2. Применение по п.1, отличающееся тем, что основную аминокислоту, ацилированную аминокислоту, L-карнитин, ацил-L-карнитин или их фармакологически приемлемые соли вводят вместе с кортикостероидами, противовоспалительными агентами, антивирусными агентами, иммунодепрессантами, цитостатическими агентами и иммуностимуляторами. 2. The use according to claim 1, characterized in that the basic amino acid, an acylated amino acid, L-carnitine, acyl-L-carnitine or their pharmacologically acceptable salts are administered together with corticosteroids, anti-inflammatory agents, antiviral agents, immunosuppressants, cytostatic agents and immunostimulants. 3. Применение изовалерил-L-карнитина для профилактики или лечения заболеваний или лечения заболеваний или цитологических нарушений, вызванных высоким содержанием церамидов, причем указанные заболевания или нарушения включают воспалительные заболевания кишечника, диффузную внутрисосудистую коагуляцию, жар, нарушения, индуцированные протеиновым катаболизмом и/или липидным истощением, гепатоспленомегалию, ассоциированную с воспалительными или метаболическими заболеваниями печени, эндо-миокардит, нарушения, индуцированные активацией эндотелиальных клеток и лейкоцитов, тромбоз капилляров, менингоэнцефалит, вызванный инфекционными агентами, нарушения, индуцированные трансплантацией органов, ревматоидный артрит и заболевания соединительных тканей, аутоиммунные заболевания, гипертиреоз, поражения радиацией и/или химиотерапевтическими агентами и синдром хронического утомления. 3. The use of isovaleryl-L-carnitine for the prevention or treatment of diseases or the treatment of diseases or cytological disorders caused by a high content of ceramides, said diseases or disorders including inflammatory bowel diseases, diffuse intravascular coagulation, fever, disorders induced by protein catabolism and / or lipid exhaustion, hepatosplenomegaly associated with inflammatory or metabolic liver diseases, endo myocarditis, disturbances induced by activation endothelial cells and leukocytes, capillary thrombosis, meningo-encephalitis due to infectious agents, disorders induced by organ transplantation, rheumatoid arthritis and connective tissue diseases, autoimmune diseases, hyperthyroidism, destruction by radiation and / or chemotherapy agents and chronic fatigue syndrome. 4. Фармацевтическая композиция, вводимая перорально или парентерально для профилактики или лечения заболеваний или цитологических нарушений, вызванных высоким содержанием церамидов, включая воспалительные заболевания кишечника, диффузную внутрисосудистую коагуляцию, нарушения, индуцированные активацией эндотелиальных клеток и лейкоцитов, тромбоз капилляров, менингоэнцефалит, вызванный инфекционными агентами, заболевания соединительных тканей и поражения радиацией, включающая в качестве активного ингредиента эффективное для снижения уровня церамида количество основной аминокислоты или ацилированной основной аминокислоты, причем основную аминокислоту выбирают из группы, состоящей из аргинина, лизина, гистидина и орнитина или их фармакологически приемлемых солей, L-карнитина или ацил-L-карнитина, где ацил выбирают из группы, состоящей из ацетила, пропионила, бутирила, валерила и изовалерила, или их фармакологически приемлемых солей, и, по крайней мере, один фармакологически приемлемый наполнитель. 4. A pharmaceutical composition administered orally or parenterally for the prevention or treatment of diseases or cytological disorders caused by high ceramides, including inflammatory bowel diseases, diffuse intravascular coagulation, disorders induced by activation of endothelial cells and white blood cells, capillary thrombosis, meningoencephalitis caused by infectious agents connective tissue diseases and radiation damage, including as an active ingredient effective for lower the level of ceramide is the amount of a basic amino acid or an acylated basic amino acid, the basic amino acid being selected from the group consisting of arginine, lysine, histidine and ornithine or their pharmacologically acceptable salts, L-carnitine or acyl-L-carnitine, where the acyl is selected from the group consisting of from acetyl, propionyl, butyryl, valeryl and isovalery, or their pharmacologically acceptable salts, and at least one pharmacologically acceptable excipient. 5. Фармацевтическая композиция, вводимая перорально или парентерально для профилактики или лечения заболеваний или цитологических нарушений, вызванных высоким содержанием церамидов, включающих воспалительные заболевания кишечника, диффузную внутрисосудистую коагуляцию, жар, нарушения, индуцированные протеиновым катаболизмом и/или липидным истощением, гепато-спленомегалию, ассоциированную с воспалительными или метаболическими заболеваниями печени, эндо-миокардит, нарушения, индуцированные активацией эндотелиальных клеток и лейкоцитов, тромбоз капилляров, менингоэнцефалит, вызванный инфекционными агентами, нарушения, вызванные трансплантацией органов, ревматоидный артрит, заболевания соединительных тканей и аутоиммунные заболевания, гипертиреоз, поражения, вызванные радиацией и/или химиотерапевтическими агентами и синдром хронического утомления, включающая в качестве активного ингредиента эффективное для снижения уровня церамида количество изовалерил-L-карнитина или его фармакологически приемлемой соли и, по крайней мере, один фармакологически приемлемый наполнитель. 5. A pharmaceutical composition administered orally or parenterally for the prophylaxis or treatment of diseases or cytological disorders caused by high ceramides, including inflammatory bowel diseases, diffuse intravascular coagulation, fever, disorders induced by protein catabolism and / or lipid depletion, hepatosplenomegaly associated with inflammatory or metabolic liver diseases, endo myocarditis, disorders induced by activation of endothelial cells and leukemia cytosis, capillary thrombosis, meningoencephalitis caused by infectious agents, disorders caused by organ transplantation, rheumatoid arthritis, connective tissue diseases and autoimmune diseases, hyperthyroidism, lesions caused by radiation and / or chemotherapeutic agents and chronic fatigue syndrome, including effective for active ingredient a decrease in ceramide levels, the amount of isovaleryl-L-carnitine or its pharmacologically acceptable salt and at least one pharmacologically acceptable filler.
RU98103503/14A 1995-08-03 1996-07-19 Application of the main amino acids and their derivatives to decrease the content of ceramides and pharmaceutical composition RU2179850C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM95A000545 1995-08-03
IT95RM000545A IT1277898B1 (en) 1995-08-03 1995-08-03 USE OF BASIC AMINO ACIDS, OF ACYL DERIVATIVES OF BASIC AMINO ACIDS AND OF THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR DISEASE PROPHYLAXIS

Publications (2)

Publication Number Publication Date
RU98103503A true RU98103503A (en) 2000-01-10
RU2179850C2 RU2179850C2 (en) 2002-02-27

Family

ID=11403513

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98103503/14A RU2179850C2 (en) 1995-08-03 1996-07-19 Application of the main amino acids and their derivatives to decrease the content of ceramides and pharmaceutical composition

Country Status (19)

Country Link
US (2) US6114385A (en)
EP (1) EP0844875B1 (en)
JP (1) JPH11510182A (en)
KR (1) KR100423760B1 (en)
CN (1) CN1138539C (en)
AR (1) AR003473A1 (en)
AT (1) ATE349206T1 (en)
AU (1) AU713207B2 (en)
BR (1) BR9610106A (en)
CA (1) CA2228281C (en)
DE (1) DE69636792T2 (en)
DK (1) DK0844875T3 (en)
ES (1) ES2279523T3 (en)
HK (1) HK1015274A1 (en)
IT (1) IT1277898B1 (en)
PT (1) PT844875E (en)
RU (1) RU2179850C2 (en)
TW (1) TW434011B (en)
WO (1) WO1997005862A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277898B1 (en) 1995-08-03 1997-11-12 Mendes Srl USE OF BASIC AMINO ACIDS, OF ACYL DERIVATIVES OF BASIC AMINO ACIDS AND OF THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR DISEASE PROPHYLAXIS
IT1277897B1 (en) * 1995-08-03 1997-11-12 Mendes Srl USE OF L-CARNITINE, ITS DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS IN COMBINATION WITH ANTIRETROVIRAL DRUGS TO REDUCE
IT1284661B1 (en) * 1996-06-06 1998-05-21 Sigma Tau Ind Farmaceuti USE OF ALCANOIL L-CARNITINE IN THE THERAPEUTIC TREATMENT OF CHRONIC INTESTINAL INFLAMMATORY DISEASES.
FR2778562B1 (en) * 1998-05-14 2000-08-04 Sephra PHARMACEUTICAL, HYGIENIC AND / OR COSMETIC COMPOSITION CONTAINING SEAWATER AND ARGININE
ES2235499T3 (en) * 1998-07-30 2005-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. USE OF PROPIONIL L-CARNITINE AND L-CARNITINE OIL DERIVATIVES IN THE PREPARATION OF MEDICINES WITH ANTI-BANERIGAN ACTIVITY.
IT1302289B1 (en) * 1998-09-30 2000-09-05 Univ Catania PHARMACEUTICAL COMPOSITIONS WITH ANTINEOPLASTIC ACTIVITY
CA2367002A1 (en) * 1999-03-19 2000-09-28 Michael A. Moskowitz Increasing cerebral bioavailability of drugs
WO2001066108A1 (en) * 2000-03-07 2001-09-13 Mucosal Therapeutics Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
EP1358878A1 (en) * 2001-01-30 2003-11-05 Ajinomoto Co., Inc. Remedies/preventives for inflammatory diseases
MXPA05004290A (en) * 2002-10-24 2005-11-23 Enos Pharmaceuticals Inc Sustained release l-arginine formulations and methods of manufacture and use.
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
IL156670A0 (en) * 2003-06-26 2004-01-04 Zvi Zolotariov Aloe suppositories
JP2007521324A (en) * 2003-09-29 2007-08-02 エノス ファーマシューティカルズ， インク． Sustained release L-arginine formulation and method for producing and using the same
JP2007055900A (en) * 2003-12-15 2007-03-08 Ajinomoto Co Inc Medicinal composition for treating and preventing inflammatory disease
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
EA019268B1 (en) * 2010-12-01 2014-02-28 Общество С Ограниченной Ответственностью "Анвилаб" Combined preparation manifesting hepatoprotective action
CN103142735B (en) * 2013-03-09 2014-07-23 河北工程大学 Traditional Chinese medicine oral liquid for treating duck virus hepatitis
EP4125858A1 (en) * 2020-04-28 2023-02-08 Lonza Consumer Health Inc. Nutritional composition comprising carnitine and method for treating or preventing an infection in a mammal
WO2023244536A2 (en) * 2022-06-13 2023-12-21 Neubase Therapeutics, Inc. Oligonucleotide analogue formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518617B2 (en) * 1977-04-29 1981-10-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutic application of acetyl-d, 1-carnitine
DE2946563A1 (en) * 1979-11-17 1981-05-21 B. Braun Melsungen Ag, 3508 Melsungen Aminoacid parenteral infusion soln. - for hepatic coma treatment contg. relatively high concns. of arginine, ornithine, glutamic acid and aspartic acid
JPH0247447B2 (en) * 1982-05-27 1990-10-19 Teijin Ltd KOHOTAIKANOHIKUIIGMSOSEIBUTSU
JPS6130567A (en) * 1984-07-23 1986-02-12 Shiseido Co Ltd Method of stabilizing urea
JPH02124822A (en) * 1988-11-02 1990-05-14 Eisai Co Ltd Cephalosporin-containing composition for injection
IT1224842B (en) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti USE OF L-CARNITINE DERIVATIVES IN THE THERAPEUTIC TREATMENT OF DEGENERATIVE ALTERATIONS OF THE NERVOUS SYSTEM
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
EP0400547A1 (en) * 1989-06-02 1990-12-05 Abbott Laboratories Parenteral nutrition product
IT1244636B (en) * 1991-01-04 1994-08-08 Sigma Tau Ind Farmaceuti USE OF ACETYL L-CARNITINE IN THERAPEUTIC TREATMENT OF COMA AND PHARMACEUTICAL COMPOSITIONS USEFUL IN SUCH TREATMENT.
IT1248321B (en) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti USE OF ACYL L-CARNITINE ESTERS WITH GAMMA-HYDROXYBUTIRRIC ACID TO PRODUCE PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATOPATHIES
IT1254136B (en) * 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti ACIL CARNITINE ESTERS WITH LONG CHAIN ALIPHATIC ALCOHOLS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, WITH ANTI-Fungal activity.
AU6922994A (en) * 1993-06-21 1995-01-17 Bernardini, Attilio Use of acylcarnitin to treat illnesses caused by aids
IT1277897B1 (en) 1995-08-03 1997-11-12 Mendes Srl USE OF L-CARNITINE, ITS DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS IN COMBINATION WITH ANTIRETROVIRAL DRUGS TO REDUCE
IT1277898B1 (en) 1995-08-03 1997-11-12 Mendes Srl USE OF BASIC AMINO ACIDS, OF ACYL DERIVATIVES OF BASIC AMINO ACIDS AND OF THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR DISEASE PROPHYLAXIS
IT1283951B1 (en) * 1996-03-15 1998-05-07 Mendes Srl USE OF ACETYL L-CARNITINE OR ITS PHARMACOLOGICALLY ACCEPTABLE SALTS FOR THERAPEUTIC TREATMENT OR PROPHYLAXIS OF

Similar Documents

Publication Publication Date Title
RU98103503A (en) APPLICATION OF BASIC AMINO ACIDS AND THEIR DERIVATIVES TO REDUCE THE CONTENT OF CERAMIDES, PHARMACEUTICAL COMPOSITION
US5753703A (en) Pharmaceutical composition comprising L-carnitine or an alkanoyl L-carnitine in combination with a polyunsaturated fatty acid of the omega-3 series for the prevention and the treatment of lipid metabolism disorders
US5084482A (en) Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
AU713207B2 (en) Use of basic aminoacids and derivatives for lowering ceramide levels
EP0787489A2 (en) Composition containing L-carnitine or alkanoyl-L-carnitine and hydroxycitric acid or pantothenic acid
JPH04226921A (en) Pharmaceutical composition for preventing, stabilizing and retroceding atherosclerosis
EP0566542B1 (en) Composition comprising L-carnitine or acyl-L-carnitine in combination with an ACE-inhibitor for the treatment of cardiovascular disorders
JP2001511447A (en) Composition comprising L-carnitine or alkanoyl L-carnitine and long chain alkanoyl
EP0590355B1 (en) Use of L-carnitine and acyl L-carnitines for treating patients suffering from aids-related syndromes and asymptomatic HIV-seropositive patients
US6380252B1 (en) Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
RU2269340C2 (en) Method for decreasing ceramide content, set comprising antiretroviral medicinal agent
FR2464715A1 (en) USE OF GLYCERYLPHOSPHORYL DERIVATIVES IN THERAPY OF DYSLIPEMIA, HEPATITIS AND SIMILAR PATHOLOGICAL CONDITIONS AND PHARMACEUTICAL COMPOSITIONS FOR THERAPY
RU98103506A (en) APPLICATION OF BASIC AMINO ACIDS AND DERIVATIVES TO REDUCE THE CONTENT OF CERAMIDES
ES2269356T3 (en) COMPOSITION THAT CONSISTS OF PROPIONIL L-CARNITINE AND GLYCINE FOR THE PREVENTION AND / OR TREATMENT OF CITOTOXIC EFFECTS INDUCED BY THE USE OF IMMUNOSUPPRESSING AGENTS.
RU2111747C1 (en) Pharmaceutical composition showing hepatoprotective effect
EP0539336A1 (en) Use of L-carnitine or of acyl L-carnitine for the treatment of idiopathic oligoasthenospermias
AU2001241031A1 (en) Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
JPH08208472A (en) Antihepatitis agent